Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 58.97

+5.6%

11:13 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dr. John M. de Castro who wrote (1341)	7/13/2000 2:31:40 PM
From: Biomaven	Read Replies (1) of 52153

John, Do you have any idea of what the FRX/Merz deal looks like? Just trying to figure what NTII stands to collect if memantine is a big drug. I'd guess something like a 2% royalty on AD, and 15% on diabetic neuropathy and Aids dementia. You have any insight? Aricept is currently heading to be a billion dollar drug (I saw a sales figure of close on $200m for Q1 of this year). How do you think sales of memantine might compare? Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next